Vantage logo

Key biotech catalysts approach

Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.

Vantage logo

The dream is over for Intercept

The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.

Vantage logo

Novo’s Nash play takes shape

As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.